The biosimilars industry and FDA will grapple with myriad regulatory shifts in 2020, with one of the most immediate challenges being the drug-to-biologic transition that some brand and generic drug makers will face next month. Stakeholders say that will have a major impact on interchangeability -- another area that’s being closely watched, as FDA’s approach will affect both development and access. Some of the lingering policy questions could be resolved through FDA guidance or congressional intervention. The most immediate change...